Vertex Pharmaceuticals (VRTX) Other Non-Current Liabilities (2009 - 2026)

Vertex Pharmaceuticals' Other Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 31.88% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (up 31.88% YoY), while the FY2025 annual figure was $1.3 billion, up 25.12% from the prior year.
• Other Non-Current Liabilities was $1.3 billion for Q1 2026 at Vertex Pharmaceuticals, down from $1.3 billion in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $1.3 billion in Q4 2025 to a low of $127.2 million in Q3 2022.
• Historically, Other Non-Current Liabilities has averaged $819.9 million across 5 years, with a median of $876.8 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities sank 30.7% in 2022, then jumped 583.41% in 2023.
• A 5-year view of Other Non-Current Liabilities shows it stood at $685.8 million in 2022, then grew by 27.98% to $877.7 million in 2023, then grew by 15.6% to $1.0 billion in 2024, then climbed by 25.12% to $1.3 billion in 2025, then retreated by 1.11% to $1.3 billion in 2026.
• The last three Other Non-Current Liabilities figures came in at $1.3 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.